BTK and B-cell chronic lymphocytic leukemia: Ibrutinib, a potent oral first-in-class BTK inhibitor, is authorized in Europe since 2014 for the treatment of adult patients with previously untreated CLL or who received at least one prior therapy for CLL (European Medicines Agency (EMA), 2019).